bearish
Celltrion (068270 KS): Increasing Biosimilar Competition- Main Concerning Factor
244 Views09 Mar 2022 00:56
SUMMARY
- Fierce competition is an industry-wide phenomena in biosimilar products. Despite being an early mover, Celltrion Inc (068270 KS) is also facing competition for its marketed biosimilars.
- The market share of Celltrion’s key biosimilar product, Remsima is declining. Other marketed and upcoming biosimilars also have multiple existing players.
- With the waning COVID-19 infections in the U.S., demand for Celltrion’s rapid test kits seems uncertain.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- Celltrion Group Companies - Sharp Increase in Dividends17 Dec 2022
- Celltrion (068270 KS): Competition Makes US Approval of New Oncology Biosimilar Unappealing30 Sep 2022
- Celltrion (068270 KS): Muted Q1 2022 Performance Reflects Continuing Biosimilars Pricing Pressure14 May 2022
- Celltrion (068270 KS): Increasing Biosimilar Competition- Main Concerning Factor09 Mar 2022
- FSC Finally Reviews Accounting Fraud Allegations of Celltrion Group After 3 Years of Investigation23 Nov 2021
- Celltrion Inc - The Minority Shareholders Upheaval & Concerns About Potential Inheritance Tax Issue15 Oct 2021
x